Sign in
Not yet recruitingPhase 2/3

DLBS1033 added to usual care for nerve damage from diabetes

Tests DLBS1033 alongside standard care in people with diabetic polyneuropathy.

Key facts

Who runs it
Universitas Sebelas Maret
Where
Indonesia1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy
Status
Not yet recruiting
Phase
Phase 2/3
People taking part
34 people, planned
Started
1 Mar 2026
Planned end
30 Jun 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • DLBS1033
  • Placebo Comparator: Placebo + Standard Therapy
Record updated
16 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who have nerve damage in the limbs from diabetes (diabetic polyneuropathy). They get DLBS1033 or placebo, added to standard therapy, for 28 days.

Age
40 to 60 years
Sex
All sexes
Disease stage
Diabetic polyneuropathy diagnosed by a neurologist or neurology resident.
Earlier treatment
People currently taking anti-inflammatory or antioxidant medicines cannot join. People who took part in another drug trial within 30 days before screening cannot join.
Biomarker or test result
HbA1c between 7-10% (53–86 mmol/mol) within the past 30 days.

Main reasons for not taking part

  • Pregnant, breastfeeding, or planning pregnancy
  • Other nerve or brain diseases, such as stroke, myelopathy, alcoholic neuropathy or compressive radiculopathy
  • Serious kidney problems (creatinine > 1.5× upper limit of normal), liver problems (SGOT or SGPT > 3× upper limit of normal), or NYHA class III-IV heart failure
  • Drinking alcohol for ≥ 5 years in a row, or heavy smoking (Brinkman Index > 600)
  • Autoimmune disease, cancer, other inflammatory conditions, or allergy to DLBS1033

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Adults aged 40-60 years diagnosed with diabetic polyneuropathy by a neurologist or neurology resident
  • Patients with HbA1c levels between 7-10% within the past 30 days
  • Willing to participate and able to sign the informed consent form

Who cannot take part

  • Participation in another interventional pharmacological clinical study within 30 days prior to screening
  • Currently taking anti-inflammatory and/or antioxidant medications
  • History of other neurological diseases such as stroke, myelopathy, alcoholic neuropathy, or compressive radiculopathy
  • History of alcohol consumption for ≥ 5 consecutive years
  • Known allergy or intolerance to DLBS1033
  • Autoimmune disease, malignancy, or acute and/or chronic inflammatory conditions other than diabetic polyneuropathy
  • Significant renal impairment (creatinine > 1.5× upper limit of normal), hepatic impairment (SGOT or SGPT > 3× upper limit of normal), or severe cardiac disease (NYHA class III-IV heart failure)
  • Pregnant, breastfeeding, or planning pregnancy
  • Heavy smoker (Brinkman Index > 600)

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 60 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to evaluate whether oral DLBS1033 can improve clinical symptoms and biological markers of nerve damage in adults with diabetic polyneuropathy. The trial enrolls patients with type 2 diabetes who show clinical signs of peripheral nerve injury.

Read full original descriptionShow less

Participants will receive either DLBS1033 as adjuvant therapy or standard therapy alone for 28 days. The study will compare changes in neuropathy severity (Toronto Clinical Neuropathy Score), inflammatory biomarkers (TNF-α), neuroregeneration biomarkers (Nerve Growth Factor), and sensory nerve conduction parameters of the sural nerve between the two groups. Blood tests, clinical assessments, and nerve conduction studies will be performed at baseline and follow-up visits. Participants will also report any symptoms or adverse events throughout the study.

The 2 groups in the trial

  • Experimental: DLBS1033 + Standard TherapyTreatment being tested

    Participants receive oral DLBS1033 as adjuvant therapy in addition to standard therapy for diabetic polyneuropathy. Intervention Drug: DLBS1033 Dose: 980 mg orally, three times daily Duration: 28 days Description: DLBS1033 contains lumbrokinase (Lumbricus low-molecular-weight proteins) with anti-inflammatory, fibrinolytic, and neuroregenerative activity. Other Components: Standard therapy for diabetic polyneuropathy (per treating physician).

    Treatment: DLBS1033 and Placebo Comparator: Placebo + Standard Therapy

  • Placebo Comparator: Placebo + Standard TherapyPlacebo, for comparison

    Participants receive placebo capsules identical in appearance to DLBS1033, in addition to standard therapy. Intervention Drug: Placebo Dose: Matching placebo, orally, three times daily Duration: 28 days Other Components: Standard therapy for diabetic polyneuropathy (per treating physician).

    Treatment: DLBS1033 and Placebo Comparator: Placebo + Standard Therapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effect of Oral DLBS1033 as Adjuvant Therapy on Inflammatory Biomarkers, Neuroregeneration Biomarkers, and Disease Severity in Patients With Diabetic Polyneuropathy: A Randomized Controlled Trial (An Evaluation of Changes in TCNS, TNF-α, NGF, and Sensory Nerve Conduction Study of the Sural Nerve)
Plain-language title
DLBS1033 added to usual care for nerve damage from diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07475065, who can take part
Record updated
16 March 2026